Nanosonics (ASX:NAN) has reached an important regulatory milestone after the United States Food and Drug Administration granted 510(k) clearance that broadens the range of endoscopes compatible with the company’s CORIS system.

Island Pharmaceuticals (ASX:ILA) has entered a strategic research collaboration with the Burnet Institute to expand the development potential of its antiviral drug portfolio and target a broader range of global viral threats.

New research presented by Amplia Therapeutics (ASX:ATX) is drawing attention to a potential strategy that could improve the effectiveness of an emerging class of cancer treatments targeting KRAS mutations, one of the most widely studied drivers of solid tumours worldwide.

Lateral Pharma has secured a significant intellectual property milestone with the granting of a U.S. composition-of-matter patent for LAT9997, the company’s next-generation therapeutic candidate targeting the LanCL pathway for the treatment of neuropathic pain.

Seven Australian medtech companies are being supported to accelerate their pathway into local procurement through a national capability program aimed at strengthening the adoption of homegrown medical technologies.

PYC Therapeutics (ASX:PYC) has completed the retail component of a major capital raising, adding approximately $47 million to its funding as the biotechnology company continues to advance its precision medicine programs for genetic diseases.

Firebrick Pharma (ASX:FRE) is preparing for a pivotal year in 2026 as it accelerates the commercial expansion of its Nasodine product portfolio and pushes into new international markets.

Alterity Therapeutics (ASX:ATH) has appointed internationally recognised neurologist Dr Daniel O Claassen as Chief Medical Advisor as the company prepares to advance its lead therapy into a pivotal late-stage clinical trial.

Australian biotechnology company AdAlta (ASX:1AD) has expanded the clinical advisory board of its subsidiary AdCella as it prepares to advance a promising new CAR-T cell therapy for solid cancers into further development and clinical testing.

Island Pharmaceuticals (ASX:ILA) has strengthened its position in the United States biodefence research network through a new collaborative agreement aimed at accelerating the development of its antiviral drug candidate, Galidesivir, for the treatment of Marburg virus disease.

Neuren Pharmaceuticals (ASX:NEU) has moved swiftly to reinforce its confidence in DAYBUE's (trofinetide) prospects in Europe, formally backing its partner Acadia Pharmaceuticals’ plan to seek a re-examination of a negative opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use.

Avecho Biotechnology (ASX:AVE) has reached a critical moment in its bid to bring an over-the-counter cannabidiol treatment for insomnia to market, announcing that it has completed recruitment for the interim analysis cohort of its pivotal Phase 3 clinical trial.

An Australian research team has uncovered what could become the first new natural anti-inflammatory therapy in more than half a century, raising hopes for a significant reduction in deaths from sepsis, one of the world’s leading causes of mortality.

Entropy Neurodynamics (ASX:ENP) has completed enrolment of the first cohort in its clinical trial of TRP 8803, an intravenously infused formulation of psilocin, marking a key operational milestone in the company’s push to develop new treatments for binge eating disorder.

Botanix Pharmaceuticals (ASX:BOT) has entered 2026 with strong commercial momentum, reporting rapid growth in prescriptions and revenue for Sofdra, its FDA-approved treatment for primary axillary hyperhidrosis, while positioning the company for improved margins and platform expansion

A new Australian study suggests that a simple blood test could help doctors better identify which head and neck cancer patients are most likely to experience a relapse after treatment.

Australian company Vaxxas has been selected as part of an international consortium to help strengthen Europe’s preparedness for future seasonal and pandemic influenza threats, securing a place in a competitive European Union tender that could unlock up to $250 million in development funding.

CLINUVEL Pharmaceuticals (ASX:CUV) has reported its strongest December half-year revenue on record, underscoring what it describes as the resilience of its commercial platform and the disciplined execution of its long-term growth strategy.